SCOTTSDALE, AZ--(Marketwire - January 07, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced today that it has modified its license agreement with the Institute of Cellular Medicine (“ICM”). This modification had the effect of: (i) revising the royalty rate from 85% of ICM’s pretax income to 20% of ICM’s gross revenues; (ii) extending the term of the agreement from expiring in 2010 to perpetuity; and (iii) removing the Company’s obligation to fund ICM pursuant to the agreement.
